Iterative Scopes obtained $150 million in series B funding to develop its artificial intelligence-powered gastroenterology technology, the company said Jan. 19.
The financing comes after the company raised $30 million in August.
Iterative Scopes will focus on inflammatory bowel disease and colorectal cancer prevention with the development of its AI technology products and services.
The company offers an automated polyp detection tool, endoscopic scoring systems and a recruitment service for pharmaceutical companies to accelerate their IBD clinical trials.